AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
- Timo grimmer is in the team - All endpoints of ... See more
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial result... See more
BXRX
Baudax Bio Inc
-52.79%
$3.41 - $1.61
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
By utilizing a specialized database, this study is... See more
Feb, 16, 2023
$NRBO check out all of the trials they have going ... See more
PALI
Palisade Bio Inc
-19.56%
$2.25 - $1.81
Feb 7th 2023 - Mar 21st 2023
Jan, 2, 2023
They voluntarily suspended phase 3 bc they are see... See more
Dec, 16, 2022
$PALI phase 2 coming WOOOOO!! !
Mar, 21, 2023
- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.
Mar, 6, 2023
$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻♂️🤦🏻♂️🤦🏻♂️😂😂😂
Mar, 5, 2023
$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.
Mar, 3, 2023
$AVXL Australia trial data meets the gold standard.
Feb, 26, 2023
The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.
Jan, 31, 2023
2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.
Jan, 28, 2023
This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.
Jan, 24, 2023
Sava has potential and the phase 3 results will show the truth.
Mar, 16, 2023
By utilizing a specialized database, this study is ensuring the utmost safety and efficacy of the medication.
Feb, 16, 2023
$NRBO check out all of the trials they have going on and backed by DONG A-ST this is the making of a MEGA RUNNER.
Jan, 24, 2023
Successful phase 2 which will be final approved April 2023 .
Jan, 14, 2023
3.67 cash per share and $20+ PT's. Not to mention, consistency with positive studies and data.
Jan, 13, 2023
Phase 3 results were solid.
Jan, 3, 2023
$BXRX must be good phase 2 data
Dec, 9, 2022
I can only imagine how useful it will be clinical setting, much like a Toradol Injection is used.
Dec, 8, 2022
$SNAP $META $GOOGL $PINS gonna go up $BXRX is just getting started imo huge phase 2 trial and great fundamentals
Dec, 8, 2022
$AFRM $UPST $SOFI $DLO good fintech companies $BXRX holy shiiii amazing news with starting their trials and great fundamentals